Total Payments
$17,720
2024 Payments
$20.75
Companies
30
Transactions
203
Medicare Patients
4,022
Medicare Billing
$640,593
Payment Breakdown by Category
Other$13,410 (75.7%)
Food & Beverage$3,293 (18.6%)
Travel$717.48 (4.0%)
Consulting$250.00 (1.4%)
Education$49.31 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $13,410 | 6 | 75.7% |
| Food and Beverage | $3,293 | 190 | 18.6% |
| Travel and Lodging | $717.48 | 2 | 4.0% |
| Consulting Fee | $250.00 | 1 | 1.4% |
| Education | $49.31 | 4 | 0.3% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $8,395 | 34 | $0 (2023) |
| Pharmacyclics LLC, An AbbVie Company | $4,424 | 8 | $0 (2019) |
| Janssen Biotech, Inc. | $2,442 | 4 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $551.01 | 38 | $0 (2017) |
| Genentech USA, Inc. | $434.93 | 27 | $0 (2017) |
| Merck Sharp & Dohme Corporation | $341.85 | 14 | $0 (2018) |
| PFIZER INC. | $182.01 | 15 | $0 (2022) |
| Amgen Inc. | $161.16 | 12 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $119.20 | 8 | $0 (2017) |
| Celgene Corporation | $92.88 | 6 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $20.75 | 1 | Novocure Inc. ($20.75) |
| 2023 | $17.43 | 1 | E.R. Squibb & Sons, L.L.C. ($17.43) |
| 2022 | $46.82 | 3 | E.R. Squibb & Sons, L.L.C. ($32.73) |
| 2021 | $11.92 | 1 | Gilead Sciences, Inc. ($11.92) |
| 2019 | $4,228 | 3 | E.R. Squibb & Sons, L.L.C. ($3,628) |
| 2018 | $10,808 | 12 | E.R. Squibb & Sons, L.L.C. ($4,500) |
| 2017 | $2,586 | 182 | Novartis Pharmaceuticals Corporation ($551.01) |
All Payment Transactions
203 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/05/2024 | Novocure Inc. | Optune Lua (NovoTTF-200T) (Device) | Food and Beverage | Cash or cash equivalent | $20.75 | General |
| Category: Oncology | ||||||
| 05/23/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Education | In-kind items and services | $17.43 | General |
| Category: Oncology | ||||||
| 10/27/2022 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $18.91 | General |
| Category: Oncology | ||||||
| 10/13/2022 | E.R. Squibb & Sons, L.L.C. | CAMZYOS (Drug) | Food and Beverage | Cash or cash equivalent | $13.82 | General |
| Category: Cardiovascular | ||||||
| 04/28/2022 | PFIZER INC. | INLYTA (Drug), BAVENCIO, LORBRENA | Food and Beverage | In-kind items and services | $14.09 | General |
| Category: ONCOLOGY | ||||||
| 06/01/2021 | Gilead Sciences, Inc. | — | Education | In-kind items and services | $11.92 | General |
| 04/30/2019 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| Category: Oncology | ||||||
| 03/19/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,505.00 | General |
| Category: Oncology | ||||||
| 03/13/2019 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $123.48 | General |
| Category: Oncology | ||||||
| 11/13/2018 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,000.00 | General |
| Category: Oncology | ||||||
| 11/13/2018 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Food and Beverage | In-kind items and services | $99.99 | General |
| Category: Oncology | ||||||
| 11/13/2018 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Travel and Lodging | In-kind items and services | $78.48 | General |
| Category: Oncology | ||||||
| 11/08/2018 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $99.60 | General |
| Category: Oncology | ||||||
| 09/26/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,505.00 | General |
| Category: Oncology | ||||||
| 09/26/2018 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,200.00 | General |
| Category: Oncology | ||||||
| 09/17/2018 | Pharmacyclics LLC, An AbbVie Company | Imbruvica (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| Category: Oncology | ||||||
| 09/13/2018 | Janssen Biotech, Inc. | IMBRUVICA (Drug) | Food and Beverage | In-kind items and services | $124.80 | General |
| Category: Oncology | ||||||
| 04/12/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Travel and Lodging | Cash or cash equivalent | $639.00 | General |
| Category: Oncology | ||||||
| 04/12/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $106.27 | General |
| Category: Oncology | ||||||
| 04/04/2018 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Consulting Fee | Cash or cash equivalent | $250.00 | General |
| Category: Oncology | ||||||
| 03/09/2018 | Merck Sharp & Dohme Corporation | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $105.30 | General |
| Category: ONCOLOGY | ||||||
| 10/13/2017 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $21.86 | General |
| Category: ONCOLOGY | ||||||
| 10/10/2017 | PFIZER INC. | IBRANCE (Drug) | Food and Beverage | In-kind items and services | $13.24 | General |
| Category: ONCOLOGY | ||||||
| 10/06/2017 | Novartis Pharmaceuticals Corporation | RYDAPT (Drug) | Food and Beverage | In-kind items and services | $16.36 | General |
| Category: HEMATOLOGY | ||||||
| 10/02/2017 | PFIZER INC. | SUTENT (Drug), INLYTA, BAVENCIO | Food and Beverage | In-kind items and services | $15.90 | General |
| Category: ONCOLOGY;RESPIRATORY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 956 | 1,425 | $339,506 | $146,457 |
| 2022 | 9 | 932 | 1,435 | $331,700 | $149,602 |
| 2021 | 7 | 996 | 1,623 | $369,890 | $177,220 |
| 2020 | 10 | 1,138 | 1,757 | $402,481 | $167,315 |
Total Patients
4,022
Total Services
6,240
Medicare Billing
$640,593
Procedure Codes
33
All Medicare Procedures & Services
33 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 261 | 454 | $126,904 | $59,260 | 46.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 316 | 541 | $115,326 | $49,239 | 42.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 198 | 234 | $33,898 | $14,587 | 43.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 82 | 82 | $32,832 | $12,366 | 37.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 35 | 37 | $14,741 | $5,019 | 34.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 26 | 26 | $8,408 | $3,102 | 36.9% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 38 | 51 | $7,397 | $2,884 | 39.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 362 | 648 | $134,190 | $58,941 | 43.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 223 | 405 | $110,148 | $53,620 | 48.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 90 | 90 | $35,052 | $15,215 | 43.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 142 | 165 | $23,251 | $9,824 | 42.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 28 | 28 | $8,787 | $3,529 | 40.2% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 32 | 32 | $8,880 | $3,402 | 38.3% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 26 | 31 | $6,420 | $3,035 | 47.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 14 | 20 | $2,712 | $1,123 | 41.4% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 15 | 16 | $2,260 | $911.52 | 40.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 397 | 747 | $150,840 | $72,518 | 48.1% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 264 | 508 | $134,689 | $68,246 | 50.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 113 | 113 | $42,824 | $18,375 | 42.9% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 163 | 191 | $26,273 | $11,897 | 45.3% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 29 | 29 | $7,852 | $3,133 | 39.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 16 | 16 | $4,896 | $1,967 | 40.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 14 | 19 | $2,516 | $1,085 | 43.1% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 284 | 571 | $147,593 | $63,023 | 42.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 398 | 698 | $137,467 | $54,866 | 39.9% |
About Dr. Neil Belman, DO
Dr. Neil Belman, DO is a Medical Oncology healthcare provider based in Easton, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/01/2005. The National Provider Identifier (NPI) number assigned to this provider is 1598759847.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Neil Belman, DO has received a total of $17,720 in payments from pharmaceutical and medical device companies, with $20.75 received in 2024. These payments were reported across 203 transactions from 30 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($13,410).
As a Medicare-enrolled provider, Belman has provided services to 4,022 Medicare beneficiaries, totaling 6,240 services with total Medicare billing of $640,593. Data is available for 4 years (2020–2023), covering 33 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Location Easton, PA
- Active Since 09/01/2005
- Last Updated 11/29/2022
- Taxonomy Code 207RX0202X
- Entity Type Individual
- NPI Number 1598759847
Products in Payments
- OPDIVO (Biological) $8,327
- Imbruvica (Drug) $4,424
- IMBRUVICA (Drug) $2,442
- KEYTRUDA (Biological) $341.85
- AFINITOR (Drug) $227.30
- Avastin (Biological) $137.86
- TECENTRIQ (Biological) $114.24
- TAGRISSO (Drug) $104.14
- KISQALI (Drug) $100.19
- Neulasta (Biological) $92.50
- TASIGNA (Drug) $92.04
- IBRANCE (Drug) $74.60
- MEKINIST (Drug) $52.83
- Revlimid (Drug) $52.46
- NINLARO (Drug) $50.69
- JEVTANA (Drug) $49.12
- Lonsurf (Drug) $48.73
- ADCETRIS (Biological) $45.27
- JAKAFI (Drug) $45.05
- Kyprolis (Biological) $40.69
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.